Medytox won the first trial of the KFDA's cancellation of administrative disposition
폴 리
hoondork1977@alphabiz.co.kr | 2023-11-10 07:22:36
[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox won an administrative suit seeking the KFDA's order to suspend manufacturing and sales of three botulinum toxin "Medytoxin" products and cancel the item license.
Global pharmaceutical bio company Medytox said on the 9th that the third administration of the Daejeon District Court has ruled the cancellation of all dispositions in a lawsuit to cancel the disposal of three medi toxin items (50, 100, 150 units) filed against the head of the Daejeon Regional Food and Drug Administration.
The Ministry of Food and Drug Safety ordered the cancellation of item licenses for the three products in 2020 in violation of the Pharmaceutical Affairs Act, saying it manipulated documents as if Medytox used an unauthorized solution and produced it as a licensed solution in the process of producing medi toxin from 2012 to 2015.
[ⓒ AlphaBIZ. 무단전재-재배포 금지]
많이 본 기사
- 1Samsung Electronics Labor Talks Collapse Again as Union Rejects “Industry-Leading” Compensation Proposal
- 2Korea Exchange Flags 76 Suspected Short-Selling Violations via Monitoring System
- 3Affinity Equity Partners Seeks Price Cut in Lotte Rental Deal Amid Antitrust Hurdles
- 4Naver Revises Dormant Account Policy for Mail Service to Cut Costs and Reduce Spam Traffic
- 5Court Dismisses Shareholder Derivative Suit Against DB HiTek Chairman Family Over Compensation Dispute
- 6Naphtha Supply Risks Trigger Packaging Shortage Concerns Across Food and Restaurant Industries